Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000820215 | SCV000960916 | pathogenic | not provided | 2023-11-20 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys561Leufs*5) in the HPS3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HPS3 are known to be pathogenic (PMID: 11590544). This variant is present in population databases (rs778152054, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with HPS3-related conditions. ClinVar contains an entry for this variant (Variation ID: 662551). For these reasons, this variant has been classified as Pathogenic. |
UNC Molecular Genetics Laboratory, |
RCV001095689 | SCV001251492 | likely pathogenic | Hermansky-Pudlak syndrome 3 | criteria provided, single submitter | research | HPS3 c.1682_1683delGT (p.C561fs) is a frameshift deletion of two nucleotides that is predicted to result in an nonfunctional HPS3 protein. This variant has not been described previously in the literature. | |
Gene |
RCV000820215 | SCV002513228 | pathogenic | not provided | 2022-05-04 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Baylor Genetics | RCV001095689 | SCV004200002 | likely pathogenic | Hermansky-Pudlak syndrome 3 | 2023-09-11 | criteria provided, single submitter | clinical testing |